Every 8-K that Cigna Group (CI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CI filings page.
The Cigna Group reported higher revenue and net income for the three months ended June 30, 2026. Total revenues were $71,668 million, up from $67,178 million a year earlier. Shareholders’ net income was $1,660 million, or $6.29 per share, compared with $1,532 million, or $5.71 per share.
Adjusted income from operations was $2,054 million, or $7.78 per share, versus $1,930 million, or $7.20, in second quarter 2025. Evernorth Health Services generated adjusted revenues of $61,468 million and pre-tax adjusted income of $1,663 million, while Cigna Healthcare delivered adjusted revenues of $11,728 million and pre-tax adjusted income of $1,276 million. In April 2026, the company announced a planned exit from the Individual and Family Plans medical business effective January 1, 2027.
As of June 30, 2026, total medical customers numbered 18,413 thousand within 182,765 thousand total customer relationships. For full year 2026, the company now expects consolidated adjusted income from operations of at least $30.45 per share, with Evernorth and Cigna Healthcare projected to generate at least $6,900 million and $4,550 million of pre-tax adjusted income, respectively.
The Cigna Group has reaffirmed its outlook for full year 2026, expecting consolidated adjusted income from operations on a per share basis of at least $30.35 per share. This confirmation will be communicated in upcoming meetings with investors and analysts.
The company explains that adjusted income from operations excludes net investment gains or losses, amortization of acquired intangible assets, certain joint venture investment results and special items that management does not view as part of normal, recurring operations. It emphasizes that this is a non-GAAP measure and not a substitute for shareholders’ net income, and notes that a reconciliation to GAAP cannot be provided on a forward-looking basis because future investment results and special items are inherently uncertain.
The Cigna Group reported strong first quarter 2026 results with broad-based growth across its businesses and a higher full-year outlook. Total revenues were $68.5 billion for the quarter, up from $65.5 billion a year earlier, driven mainly by pharmacy-related operations. Shareholders’ net income rose to $1.65 billion, or $6.26 per share, compared with $1.32 billion, or $4.85 per share, in first quarter 2025.
Adjusted income from operations was $2.06 billion, or $7.79 per share, versus $1.84 billion, or $6.74 per share, a year ago. Evernorth Health Services generated $58.4 billion in adjusted revenues and $1.47 billion in pre-tax adjusted income, while Cigna Healthcare delivered $11.5 billion in adjusted revenues and $1.51 billion in pre-tax adjusted income with a 13.2% pre-tax margin. The company now expects full-year 2026 consolidated adjusted income from operations of at least $30.35 per share, modestly above its prior projection.
The Cigna Group reported the results of its 2026 annual shareholder meeting, where 237,225,441 shares were represented out of 263,660,761 entitled to vote, a participation rate of 89.97%.
Shareholders elected all 12 director nominees and gave advisory approval to executive compensation with 201,746,941 votes for and 17,359,954 against, with 513,936 abstentions. They ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 with 216,061,458 votes for and 21,030,077 against. A shareholder proposal to allow action by written consent did not pass, receiving 104,982,574 votes for and 114,173,793 against.
The Cigna Group announced a planned leadership transition and reaffirmed its 2026 financial outlook. Brian C. Evanko, currently president and chief operating officer, will become chief executive officer on July 1, 2026, succeeding David M. Cordani, who will retire as CEO and become executive chair of the board.
The board also elected Evanko as a director effective April 1, 2026, and named Eric J. Foss lead independent director, while revising committee leadership across audit, governance, finance and technology, and people resources. Effective July 1, 2026, Evanko’s compensation will include a $1,300,000 base salary, a $2,600,000 Enterprise Incentive Plan target and a $15,100,000 long‑term incentive target, plus a one‑time $3,500,000 transitional equity award tied to assuming the CEO role. Cordani, as executive chair, will receive a $1,000,000 base salary and a $2,000,000 incentive target.
The company reaffirmed projected full‑year 2026 consolidated adjusted income from operations of at least $30.25 per share, along with Evernorth pre‑tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare pre‑tax adjusted income from operations of at least $4.5 billion, using its non‑GAAP adjusted income from operations metric.
The Cigna Group filed an update affirming its outlook for 2026. Company officials expect full-year 2026 consolidated adjusted income from operations of at least $30.25 per share, and plan to communicate this reaffirmed guidance in upcoming meetings with investors and analysts.
The filing explains that adjusted income from operations is a non-GAAP profit measure that starts from shareholders’ net income and removes net investment gains or losses, amortization of acquired intangibles, special items, and certain joint venture investment results. It emphasizes that this metric is used internally to analyze underlying business performance and trends.
The company notes it cannot reasonably reconcile this forward-looking non-GAAP measure to GAAP shareholders’ net income because future investment results and special items are unpredictable and may vary materially. Extensive cautionary language highlights risks such as healthcare cost trends, regulatory changes, technology and cybersecurity issues, economic conditions, and execution on strategic initiatives, all of which could cause actual results to differ from the outlook.
The Cigna Group filed a current report to note that it issued a press release on February 5, 2026, covering its results for the three months and year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities laws.
The Cigna Group reported that its Board of Directors approved changes to the Board’s committee structure on October 22, 2025, with an effective date of January 1, 2026. The Board undertook a comprehensive review to ensure committee responsibilities align with the company’s strategic priorities, remain balanced, and allow the full Board to spend more time on significant matters.
The changes include adjustments to the responsibilities of the Compliance Committee and updates to the oversight of technology at the Board level. The People Resources Committee’s responsibilities remain without material changes. Detailed descriptions of each committee’s responsibilities are available in their charters on the company’s website.
The Cigna Group furnished an update on quarterly performance. The company issued a press release announcing results for the three months ended September 30, 2025, and made it available as Exhibit 99.1.
The information was furnished, not filed, under the Securities Exchange Act of 1934. Common stock trades on the NYSE under the symbol CI. No additional financial details are included in this excerpt.
The Cigna Group announced that Retired Major General Elder Granger, M.D., will retire from its Board of Directors effective December 31, 2025.
The company said his retirement is consistent with the Board’s retirement age policy and is not the result of any disagreement with the Company. Dr. Granger informed the Board on October 15, 2025.
The Cigna Group filed an 8-K reporting the filing of transaction-related exhibits dated September 2 and September 4, 2025. The company attached an Underwriting Agreement dated September 2, 2025 between The Cigna Group and BofA Securities, Citigroup, HSBC Securities (USA) and Morgan Stanley as representatives of the underwriters. It also included Supplemental Indenture No. 8 dated September 4, 2025 with U.S. Bank Trust Company, National Association as trustee, a legal opinion of Davis Polk & Wardwell LLP, and that firm’s consent. The filing identifies the company’s principal executive office in Bloomfield, Connecticut and trading symbol CI on the NYSE.
The Cigna Group filed an update stating that company officials expect to reaffirm their outlook for full year 2025, targeting consolidated adjusted income from operations of at least $29.60 per share. This guidance will be reiterated in upcoming meetings with investors and analysts, and is consistent with the outlook previously discussed in a July 31, 2025 press release and conference call.
The company explains that adjusted income from operations is a non-GAAP profitability measure that starts from shareholders’ net income and excludes net investment gains and losses, amortization of acquired intangible assets, certain joint venture investment results and special items that management views as not representative of underlying operations. Cigna notes that it cannot provide a forward-looking reconciliation to shareholders’ net income because items like future investment results and special items are inherently uncertain and could vary materially.